



Viva Biotech Announced 2020 Annual Results

Revenue Grew by 115.7% YoY, Revenue from CFS Business Increased Significantly by 146.3%

On March 30, 2021, Viva Biotech announced that during the year ended December 31, 2020, revenue of the Group increased significantly to RMB697.0 million from RMB323.1 million for the corresponding period last year, representing a YoY increase of 115.7%; gross profit increased substantially to RMB304.9 million from RMB155.9 million for the corresponding period last year, representing a YoY increase of 95.6%. The global drug R&D and production service industry continued demonstrating an upbeat trend in 2020. Viva Biotech proactively grasped the opportunity and achieved both internal growth and external expansion. The synergistic effects of the Group's CFS model and EFS model were further demonstrated. The Group has thus made substantial progress in vertical integration and expansion along the industry chain to CDMO business.

Viva Biotech 2021 Partnership Summit was Successfully Held

On March 2-6, 2021, Viva Biotech 2021 Partnership Summit was successfully held. More than 230 representatives of global investment institutions, R&D representatives of pharmaceutical companies and business development leaders participated in this summit, conducted over 300 one-to-one exchanges with the founders of over 60 incubation companies through the Partnering Platform.



Viva Biotech Completed the Acquisition of the Entire Equity Interest in Synthesis

On March 5, 2021, Viva Biotech announced the completion of the acquisition of the entire equity interest in SYNthesis med chem (Hong Kong) Limited, at the consideration of approximately US\$66.52 million. This acquisition is of great strategic significance for Viva Biotech to vertically integrate the industry chain and establish a comprehensive one-stop drug service platform.



Relocation of Viva Biotech Innovation Center



In March 2021, Viva Biotech's EFS Investment Incubation and Cooperative R&D Center moved to a new location. The new address is No. 50, Lane 63, Faladi Road, Pudong, Shanghai. It is located in the core area of Zhangjiang Science City, covering an area of about 12 acres and a laboratory area of more than 5,000 square meters.

The Environmental Impact Report of Viva Biotech's Subsidiary Langhua Pharmaceutical was Approved

On January 27, 2021, Zhejiang Langhua Pharmaceutical Co., Ltd., a non-wholly-owned subsidiary of Viva Biotech, has recently obtained a reply from Taizhou Ecological Environment Bureau, which approved Langhua Pharmaceutical's environmental impact report regarding the Company's proposed production of certain pharmaceutical intermediates and active pharmaceutical ingredients in Zhejiang Province Chemical Active Pharmaceutical Ingredient Base. Langhua Pharmaceutical intends to implement the production plans set forth in the environmental impact report, which are expected to benefit the Company in facilitating its business growth, increasing its production capabilities and capacities.



Market Recognition

Viva Biotech won the Frost & Sullivan "2021 Greater China CRO Entrepreneurial Company of the Year"



On April 15, 2021, Frost & Sullivan, an international authoritative consulting agency, announced the selection results of the 2021 Best Practices Awards. As a comprehensive one-stop drug R&D and production service platform, Viva Biotech won the "2021 Greater China CRO Entrepreneurial Company of the Year".

Viva Biotech won the "Best Small and Medium-sized Market Value Company" in the 5th Hong Kong Golden Stocks Awards

On January 6, 2021, the "5th Hong Kong Golden Stocks Awards Ceremony" co-sponsored by Zhitongcaijing, the Hong Kong and US stock information platform, and Tonghuashun (10jka.com.cn) was successfully held in Shenzhen. Viva Biotech won the "Best Small and Medium-sized Market Value Company" award.



Investment Progress



AlxplorerBio Completed an Angel Round of Financing of RMB50 Million

On April 26, 2021, AlxplorerBio, an AI new drug research and development company, announced the completion of an angel round of financing of RMB50 million. This round of financing was led by BioMap, and co-invested by Viva. As the strategic investors, BioMap and Viva Biotech will provide AlxplorerBio with comprehensive and in-depth support in AI technology, computing power, underlying multi-dimensional data, protein structure analysis, and pharmaceutical testing, etc..



VivaVision Completed Series D Financing of RMB300 Million

On April 19, 2021, VivaVision, a leading ophthalmology novel drug developer, announced that it has completed a RMB300 million Series D financing. This round of funding will be used to support the clinical development of several innovative ophthalmic drug products, including the ongoing dry eye disease project VVN001 Phase II US clinical study.



TechnoDerma Medicines Completed Tens of Millions in Series A Financing

On April 7, 2021, TechnoDerma Medicines, which focused on the development of First-in-Class new drugs for skin-related diseases, announced the completion of tens of millions in Series A financing. The funding will be used to advance the Company's pipeline clinical trials and follow-up research and development, further expand the indications, and strengthen the development of the research and development team.



AmacaThera Announced the Completion of C\$10.3 Million Series A financing

On March 11, 2021, AmacaThera, a biotech start-up company dedicated to the research and development of therapeutic delivery and stable release technologies for a variety of diseases, announced that it has completed an oversubscribed C\$10.3 million Series A financing to support development of AMT-143, AmacaThera's lead clinical asset, and pipeline expansion.



DTx Pharma Completed Series B Financing of US\$100 Million

On March 2, 2021, DTx Pharma, a biotech company dedicated to the development of RNA-based therapies that can be applied to treat genetically-defined diseases, recently announced the completion of a US\$100 million Series B financing.

Research & Development Progress

Anji Pharmaceuticals Accelerates Phase II Clinical Study of Innovative Therapy for Functional Constipation



On April 20, 2021, Anji Pharmaceuticals, a biopharmaceutical company invested and incubated by Viva BioInnovator, announced that the phase II clinical proof-of-concept study of pradigastat (ANJ908), the world's first functional constipation treatment drug, has been launched simultaneously in the United States and China. Despite the challenge of the global epidemic, the study is still progressing smoothly, and many subjects have completed medication.

The IND Application of QureBio Q-1802 Was Approved by FDA, and the Clinical Application Was Accepted by CDE



On February 27, 2021, QureBio.Ltd, a company focuses on the research and development of innovative macromolecular biopharmaceuticals, announced that the U.S. Food and Drug Administration had granted IND approval for its self-developed recombinant against Claudin 18.2 and PD-L1 humanized bispecific antibody for injection (code: Q-1802). Prior to this, on December 30, 2020, the Center For Drug Evaluation(CDE) of National Medical Products Administration(NMPA) had already accepted the Q-1802 submitted as "Therapeutic Biological Products Class 1 New Drugs" clinical trial application.



About Viva Biotech

Listing Date

2019.05.09

Price (2021.4.27)

HKD 6.81

52 WK Range

HKD 4.46 - 11.18

Market Cap (2021.4.27)

HKD 13.11B

Viva Biotech's mission is to become a cradle for innovative biotechnology companies from around the world. We have developed a scalable business model combining the conventional cash-for-service (CFS) model and its unique equity-for-service (EFS) model. Under the CFS model, the Group provides one-stop service for novel drug discovery and production to global pharmaceutical clients. EFS business is dedicated to investing globally in biotech innovation with novel solutions to unmet medical needs across multiple therapeutic areas. As of December 31, 2020, Viva Biotech had provided drug discovery and production services to 1,252 pharmaceutical clients worldwide, worked on over 1,500 independent drug targets, delivered approximately over 21,000 independent protein structures and incubated/invested 67 biotech companies.

Investor & Media Enquiries

Viva Biotech Holdings website: www.vivabiotech.com.cn

For further information, please contact: Tel: 852-3150 6788
Email: ir@vivabiotech.com; VivaBiotech.hk@pordahavas.com